Folliculotropic mycosis fungoides of the face successfully treated combining CO2 laser and conventional photodynamic therapy (c-PDT)

Photodiagnosis Photodyn Ther. 2024 Dec:50:104377. doi: 10.1016/j.pdpdt.2024.104377. Epub 2024 Oct 16.

Abstract

A 57-year-old male with a three-year history of folliculotropic mycosis fungoides (FMF), previously treated systemically, received CO2 laser-assisted photodynamic therapy (PDT) following the recurrence of FMF on the face. The procedure involved a CO2 laser (SmartXide DOT Deka) and the photosensitizing agent methyl aminolevulinate (MAL) (METVIX 160 mg/g Cream, Galderma Medical), in conjunction with a red light-emitting diode lamp (Aktilite CL128, Galderma, wavelength 630 nm). The primary endpoint was the clinical remission of the lesions; the secondary one the evaluation of treatment tolerance, measured using the 11-point (0-10) Numeric Rating Scale (NRS) for burning/pain, heat, and swelling. After a single treatment session and four weeks of follow-up, the patient's facial lesions achieved complete clinical remission.

Keywords: CO2 laser; FMF; Folliculotropic mycosis fungoides; Mycosis fungoides; PDT; Photodynamic therapy.

Publication types

  • Case Reports

MeSH terms

  • Aminolevulinic Acid* / analogs & derivatives
  • Aminolevulinic Acid* / therapeutic use
  • Combined Modality Therapy
  • Facial Neoplasms / drug therapy
  • Humans
  • Lasers, Gas* / therapeutic use
  • Male
  • Middle Aged
  • Mycosis Fungoides* / drug therapy
  • Photochemotherapy* / methods
  • Photosensitizing Agents* / therapeutic use
  • Skin Neoplasms* / drug therapy
  • Treatment Outcome

Substances

  • Photosensitizing Agents
  • Aminolevulinic Acid
  • methyl 5-aminolevulinate